Skip to main content
NVDA+0.88%AAPL+0.95%MSFT-0.22%GOOGL+1.25%AMZN+1.68%TSM+2.92%SPCX+1.38%AVGO+3.92%TSLA+3.99%META-1.67%LLY+0.31%BRK-B-0.82%MU+2.63%SKHY+2.12%WMT-0.77%AMD+5.38%JPM+0.70%V-0.66%XOM-2.35%JNJ+0.90%ASMLa+2.80%MA-0.51%ABBV+0.06%INTC+3.37%1398.HK+2.15%CVX-1.47%0700.HK-0.31%CSCO+1.01%COST-1.28%ORCL+3.59%KO-1.24%UNH-0.17%PG-0.33%BAC+0.37%1816.HK+1.32%3988.HK+0.66%CAT+3.22%DELL+7.35%HD+0.03%PM+0.97%0857.HK-0.98%AMAT+1.89%AP2d+2.18%0939.HK+0.81%GE+3.48%1288.HK+0.60%LRCX+1.25%NVS+1.91%0005.HK-5.56%MS+2.09%USDJPY+0.68%NZDMXN+0.66%EURUSD-0.59%AUDJPY+0.59%USDMXN+0.58%AUDDKK+0.51%EURAUD-0.50%EURZAR-0.48%EURSEK-0.45%GBPUSD-0.45%USDCHF+0.43%NZDJPY+0.42%GBPTRY+0.41%EURCNH-0.40%CADJPY+0.37%EURHKD-0.36%EURNZD-0.36%GBPAUD-0.35%GBPZAR-0.35%AUDCHF+0.35%USDDKK+0.34%EURSGD-0.33%USDCAD+0.33%GBPHKD+0.32%GBPMXN-0.28%CHFJPY+0.26%AUDNOK+0.26%SGDJPY+0.26%EURCAD-0.26%EURNOK-0.26%NZDUSD-0.25%USDPLN+0.24%AUDCAD+0.23%GBPJPY+0.22%CHFSEK-0.21%GBPSGD-0.20%GBPNZD-0.19%NOKJPY+0.19%AUDSGD+0.18%EURCHF-0.18%USDTRY+0.18%NZDCHF+0.17%USDILS+0.16%AUDNZD+0.15%EURGBP-0.14%GBPCAD-0.14%USDZAR-0.13%USDSEK-0.11%CADCHF+0.11%EURPLN-0.11%EURJPY+0.10%AUDUSD-0.09%NZDSGD+0.09%USDNOK+0.09%CHFSGD-0.09%NZDCAD+0.06%EURCZK-0.05%USDCNH-0.05%USDHKD+0.04%USDCOP-0.04%PLNJPY+0.04%GBPCHF-0.03%USDSGD+0.01%CHFNOK-0.01%USDTHB+0.01%EURDKK0.00%HG1+1.71%USOIL-1.27%GAUUSD+1.10%XAUUSD+1.10%XNGUSD+1.09%GAGUSD+0.88%XAGUSD+0.88%UKOIL-0.81%XPTUSD+0.65%SUGAR0.00%COTTON0.00%C10.00%BTCUSD+0.86%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.40%ZECUSDT+5.55%DOGEUSD+20.65%XMRUSDT+1.06%LINKUSD+25.58%BCHUSDT+3.15%XLMUSD+0.48%UNIUSD-0.77%LTCUSD+17.89%SUIUSD+1.06%HBARUSDT-1.33%TONUSD+41.71%TAOUSDT+1.00%AAVEUSD-2.55%DOTUSDT-1.19%ICPUSDT-1.48%ONDOUSDT+0.27%WLDUSDT+0.60%ARBUSDT-0.39%JUPUSDT+1.02%INJUSDT+0.95%ATOMUSDT-1.43%STXUSDT-1.08%TIAUSDT-0.88%PYTHUSDT-2.98%FETUSDT+3.58%SEIUSDT+0.54%IMXUSDT-0.66%GRTUSDT+1.74%OPUSDT-0.20%WIFUSDT-0.06%IOTAUSDT+0.26%POLUSDT+0.80%AXSUSDT+0.57%EOSUSDT+0.81%FARTCOINUSDT+2.41%DYDXUSDT+3.12%GALAUSDT+1.56%ORDIUSDT+2.15%RONINUSDT+1.89%NOTUSDT+1.92%NVDA+0.88%AAPL+0.95%MSFT-0.22%GOOGL+1.25%AMZN+1.68%TSM+2.92%SPCX+1.38%AVGO+3.92%TSLA+3.99%META-1.67%LLY+0.31%BRK-B-0.82%MU+2.63%SKHY+2.12%WMT-0.77%AMD+5.38%JPM+0.70%V-0.66%XOM-2.35%JNJ+0.90%ASMLa+2.80%MA-0.51%ABBV+0.06%INTC+3.37%1398.HK+2.15%CVX-1.47%0700.HK-0.31%CSCO+1.01%COST-1.28%ORCL+3.59%KO-1.24%UNH-0.17%PG-0.33%BAC+0.37%1816.HK+1.32%3988.HK+0.66%CAT+3.22%DELL+7.35%HD+0.03%PM+0.97%0857.HK-0.98%AMAT+1.89%AP2d+2.18%0939.HK+0.81%GE+3.48%1288.HK+0.60%LRCX+1.25%NVS+1.91%0005.HK-5.56%MS+2.09%USDJPY+0.68%NZDMXN+0.66%EURUSD-0.59%AUDJPY+0.59%USDMXN+0.58%AUDDKK+0.51%EURAUD-0.50%EURZAR-0.48%EURSEK-0.45%GBPUSD-0.45%USDCHF+0.43%NZDJPY+0.42%GBPTRY+0.41%EURCNH-0.40%CADJPY+0.37%EURHKD-0.36%EURNZD-0.36%GBPAUD-0.35%GBPZAR-0.35%AUDCHF+0.35%USDDKK+0.34%EURSGD-0.33%USDCAD+0.33%GBPHKD+0.32%GBPMXN-0.28%CHFJPY+0.26%AUDNOK+0.26%SGDJPY+0.26%EURCAD-0.26%EURNOK-0.26%NZDUSD-0.25%USDPLN+0.24%AUDCAD+0.23%GBPJPY+0.22%CHFSEK-0.21%GBPSGD-0.20%GBPNZD-0.19%NOKJPY+0.19%AUDSGD+0.18%EURCHF-0.18%USDTRY+0.18%NZDCHF+0.17%USDILS+0.16%AUDNZD+0.15%EURGBP-0.14%GBPCAD-0.14%USDZAR-0.13%USDSEK-0.11%CADCHF+0.11%EURPLN-0.11%EURJPY+0.10%AUDUSD-0.09%NZDSGD+0.09%USDNOK+0.09%CHFSGD-0.09%NZDCAD+0.06%EURCZK-0.05%USDCNH-0.05%USDHKD+0.04%USDCOP-0.04%PLNJPY+0.04%GBPCHF-0.03%USDSGD+0.01%CHFNOK-0.01%USDTHB+0.01%EURDKK0.00%HG1+1.71%USOIL-1.27%GAUUSD+1.10%XAUUSD+1.10%XNGUSD+1.09%GAGUSD+0.88%XAGUSD+0.88%UKOIL-0.81%XPTUSD+0.65%SUGAR0.00%COTTON0.00%C10.00%BTCUSD+0.86%ETHUSD+23.96%USDTUSD+0.06%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT+0.40%ZECUSDT+5.55%DOGEUSD+20.65%XMRUSDT+1.06%LINKUSD+25.58%BCHUSDT+3.15%XLMUSD+0.48%UNIUSD-0.77%LTCUSD+17.89%SUIUSD+1.06%HBARUSDT-1.33%TONUSD+41.71%TAOUSDT+1.00%AAVEUSD-2.55%DOTUSDT-1.19%ICPUSDT-1.48%ONDOUSDT+0.27%WLDUSDT+0.60%ARBUSDT-0.39%JUPUSDT+1.02%INJUSDT+0.95%ATOMUSDT-1.43%STXUSDT-1.08%TIAUSDT-0.88%PYTHUSDT-2.98%FETUSDT+3.58%SEIUSDT+0.54%IMXUSDT-0.66%GRTUSDT+1.74%OPUSDT-0.20%WIFUSDT-0.06%IOTAUSDT+0.26%POLUSDT+0.80%AXSUSDT+0.57%EOSUSDT+0.81%FARTCOINUSDT+2.41%DYDXUSDT+3.12%GALAUSDT+1.56%ORDIUSDT+2.15%RONINUSDT+1.89%NOTUSDT+1.92%
CP

Crinetics Pharmaceuticals, Inc. (CRNX)

NASDAQ • Healthcare

$84.95
+$0 (+0.0%)
Market closed

Last close at September 2, 2026 at 20:00 UTC

Open$84.95
Day Range$84.95 - $84.95
Avg. Volume (3M)0
Market Cap$9B
52 Week Range
$32.3$85.01

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$25.1M100%
Gross Profitminus cost of goods$24.9M99%

Fundamentals & Financials

Revenue (TTM)
$42.1M
Net Income (TTM)
-$501.6M
EPS (TTM)
-$5.05
ROA (TTM)
-37.95%
Current Ratio
15.57

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+5.8%Q1 2026-$1.29
-0.8%Q2 2026-$1.23
+3.4%Q3 2026-$1.14

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +3.4%

Crinetics Pharmaceuticals’ second fiscal quarter of 2026 earnings topped consensus on EPS, with -$1.14 coming in better than the -$1.18 estimate by $0.04, as the company reported results on August 3, 2026. The quarter’s profitability remained negative, with operating income of about -$132.5 million and net income of roughly -$120.9 million, a -4.5% year-over-year move from about -$115.6 million a year ago. Cash burn also continued, with negative operating cash flow of around -$94.2 million, consistent with its clinical-stage focus on advancing oral drug candidates for endocrine disorders and related tumors, including its Paltusotine program. Consensus for the next period calls for EPS of -$1.20 on revenue of $21.0 million.

Next report — what to expect

Crinetics Pharmaceuticals, Inc. (CRNX) is scheduled to report earnings on November 5, 2026. With consensus EPS and revenue listed as n/a, focus stays on execution and any updates tied to quarterly results. Historically, the company has beaten EPS in 3 of its 8 most recent quarters.

View full earnings history

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company developing oral drug candidates for endocrine disorders and related tumors. In qualitative terms, it is a clinical-stage pharmaceutical enterprise rather than a commercial drugmaker, with its work centered on non-peptide therapies that target hormone-signaling pathways.

Name
Crinetics Pharmaceuticals, Inc.
CEO
R. Scott Struthers
Website
www.crinetics.com
Industry
Healthcare
Year Founded
2008
Employees
594

Today's Snapshot

AI-generated

So far today, CRNX is trading flat at 84.95, in line with a flat sector. CRNX is trading within 0.1% of its 52-week high of 85.01. CRNX is due to report earnings on 5 November.

vs S&P 500 Today

Underperforming Market

-0.53%

Updated: October 27, 2026 at 19:31 UTC

CRNX Headlines

Vertex to buy Crinetics for $10 billion

July 6, 2026

3 min read
View All News

Technical Indicators

5 Buy1 Neutral2 Sell
CRNX displays a powerful trending setup: ADX is extremely high (over 80), confirming a dominant trend while OBV shows heavy accumulation and the stock trades well above its short- and long-term averages near 85. Short-term momentum indicators are overbought, with RSI and stochastic in the upper 80s–90s, however MACD is mildly positive and ATR is very low, implying tight price action despite the trend. Overall, volume and trend confirm strength even as oscillators are extended. Technical takeaway: Strong Buy — very strong trend and positive volume, tempered by overbought short-term indicators.
All signals
  • EMA (5 indicators)$52.73 - $84.82
    Buy
  • RSI (14)89.79
    Sell
  • Stochastic %K (14, 3, 3)90.77
    Sell
  • MACD Level (12, 26)2.06
    Neutral

Peers & Related Assets

KYMRKymera Therapeutics, Inc.
$114.84+3.7%
PRAXPraxis Precision Medicines, Inc.
$267.39+5.7%
IMVTImmunovant, Inc.
$28.17-0.8%
XENEXenon Pharmaceuticals Inc.
$35.77+1.2%
ACADAcadia Pharmaceuticals Inc.
$19.74+0.1%
DYNDyne Therapeutics, Inc.
$15.72+0.6%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.